For the Inventor, By the Inventor

Enter assignee name

Bridgewater, NJ, United States of America

Insmed Incorporated

USPTO Granted Patents = 64

CIPO Patents = 5

EPO Patents = 25

Trademarks = 10

Forward Citations = 894

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Vladimir Malinin (21 out of 23 patents)

Renu Gupta (19 out of 19 patents)

Adam Plaunt (14 out of 14 patents)

4. Walter Perkins (14 out of 14 patents)

5. Gina Eagle (13 out of 14 patents)

6. Jeff Weers (11 out of 11 patents)

7. Donna M Konicek (10 out of 10 patents)

8. Franziska Leifer (8 out of 8 patents)

9. Zhili Li (8 out of 9 patents)

10. Brian S Miller (4 out of 7 patents)

11. Lawrence T Boni (3 out of 17 patents)

12. Xingong Li (3 out of 5 patents)

13. Mark C Sleevi (3 out of 6 patents)

14. Ju Du (3 out of 3 patents)

15. David C Hopp (3 out of 3 patents)

Core Competencies:

DPP1 Inhibitors

Pulmonary Infections

Liposomal Drug Products

Treprostinil Prodrugs

Deimmunized Lysostaphin

Prostacyclin Compounds

Lipo-Glycopeptide Derivatives

Antibodies

Stabilized Vancomycin

Multicationic Drugs

Sustained Release

Platinum Compounds

64 patents: Sort by Forward Citations

1. 12479837 - Reversible DPP1 inhibitors and uses thereof (2025-11-25),

2. 12377114 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2025-08-05),

3. 12290600 - Methods for continuous manufacture of liposomal drug products (2025-05-06),

4. 12201725 - Dry powder compositions of treprostinil prodrugs and methods of use thereof (2025-01-21),

5. 12168022 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2024-12-17),

6. 12168021 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2024-12-17),

7. 12104186 - Deimmunized lysostaphin and methods of use (2024-10-01),

8. 12016873 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2024-06-25),

9. 11998553 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis (2024-06-04),

10. 11857597 - Lipo-glycopeptide cleavable derivatives and uses thereof (2024-01-02),

11. 11795135 - Prostacyclin compounds, compositions and methods of use thereof (2023-10-24),

12. 11759425 - Dry powder compositions of treprostinil prodrugs and methods of use thereof (2023-09-19),

13. 11649291 - Antibodies and methods of making same (2023-05-16),

14. 11571386 - Methods for continuous manufacture of liposomal drug products (2023-02-07),

15. 11458098 - Dry powder compositions of treprostinil prodrugs and methods of use thereof (2022-10-04),

INSMED is a global biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare diseases. The company's goal is to transform the lives of patients through scientific innovation and has a diverse pipeline of investigational drugs targeting serious unmet medical needs. With a commitment to improving patient outcomes, INSMED aims to advance solutions that make a meaningful impact in the rare disease community.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

64 Patents

#9 in Bridgewater, NJ

#239 in New Jersey

#5,446 in US

#11,029 in the World

Bridgewater, NJ, United States of America

Insmed Incorporated

Forward Citations = 894

45 inventors:

Vladimir Malinin (21 out of 23 patents)

Renu Gupta (19 out of 19 patents)

Adam Plaunt (14 out of 14 patents)

4. Walter Perkins (14 out of 14 patents)

5. Gina Eagle (13 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…